HYP-2090PTSA

· Sichuan Huiyu Pharmaceutical Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HYP-2090PTSA, covering 2026-01-29 to 2026-01-29. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation [Phase 1, Phase 2]